Current Treatment and Future Trends of Immunotherapy in Breast Cancer

Author:

Cescon David W.1ORCID,Elliott Mitchell J.1ORCID,Wilson Brooke12ORCID

Affiliation:

1. Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre and The University of Toronto, Toronto, Ontario, Canada

2. University of New South Wales, Kensington, New South Wales, Australia

Abstract

Abstract: Immunotherapy continues to redefine the solid tumor treatment landscape, with inhibitors of the PD-L1/PD-1 immune checkpoint having the most widespread impact. As the most common cancer diagnosed worldwide, there is significant interest in the development of immunotherapy for the treatment of breast cancer in both the early and metastatic settings. Recently reported results of several clinical trials have identified potential roles for immunotherapy agents alone or in combination with standard treatment for early and metastatic disease. While trials to date have been promising, immunotherapy has only been shown to benefit a select group of patients with breast cancer, defined by tumor subtype, PD-L1 expression, and line of therapy. With over 250 trials ongoing, emerging data will enable the further refinement of breast cancer immunotherapy strategies. The integration of multiple putative biomarkers and consideration of dynamic markers of early response or resistance may inform optimal patient selection for immunotherapy investigation and integration into clinical practice. This review will summarize the current evidence for immune-checkpoint blockade (ICB) in the treatment of early and metastatic breast cancer, highlighting current and potential future biomarkers of therapeutic response.

Publisher

Bentham Science Publishers Ltd.

Subject

Cancer Research,Drug Discovery,Pharmacology,Oncology

Reference89 articles.

1. Gradishar W.J.; NCCN clinical practice guidelines in oncology (NCCN Guidelines®): Breast cancer version 4. Available from: 2021

2. Thorsson V.; Gibbs D.L.; Brown S.D.; Wolf D.; Bortone D.S.; Ou Yang, T.H.; Porta-Pardo, E.; Gao, G.F.; Plaisier, C.L.; Eddy, J.A.; Ziv, E.; Culhane, A.C.; Paull, E.O.; Sivakumar, I.K.A.; Gentles, A.J.; Malhotra, R.; Farshidfar, F.; Colaprico, A.; Parker, J.S.; Mose, L.E.; Vo, N.S.; Liu, J.; Liu, Y.; Rader, J.; Dhankani, V.; Reynolds, S.M.; Bowlby, R.; Califano, A.; Cherniack, A.D.; Anastassiou, D.; Bedognetti, D.; Mokrab, Y.; Newman, A.M.; Rao, A.; Chen, K.; Krasnitz, A.; Hu, H.; Malta, T.M.; Noushmehr, H.; Pedamallu, C.S.; Bullman, S.; Ojesina, A.I.; Lamb, A.; Zhou, W.; Shen, H.; Choueiri, T.K.; Weinstein, J.N.; Guinney, J.; Saltz, J.; Holt, R.A.; Rabkin, C.S.; Lazar, A.J.; Serody, J.S.; Demicco, E.G.; Disis, M.L.; Vincent, B.G.; Shmulevich, I. The immune landscape of cancer. Immunity 2019,51(2),411-412

3. Azizi E.; Carr A.J.; Plitas G.; Cornish A.E.; Konopacki C.; Prabhakaran S.; Nainys J.; Wu K.; Kiseliovas V.; Setty M.; Choi K.; Fromme R.M.; Dao P.; McKenney P.T.; Wasti R.C.; Kadaveru K.; Mazutis L.; Rudensky A.Y.; Pe’er D.; Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 2018,174(5),1293-1308.e36

4. Loi S.; Sirtaine N.; Piette F.; Salgado R.; Viale G.; Van Eenoo F.; Rouas G.; Francis P.; Crown J.P.; Hitre E.; de Azambuja E.; Quinaux E.; Di Leo A.; Michiels S.; Piccart M.J.; Sotiriou C.; Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013,31(7),860-867

5. Dieci M.V.; Criscitiello C.; Goubar A.; Viale G.; Conte P.; Guarneri V.; Ficarra G.; Mathieu M.C.; Delaloge S.; Curigliano G.; Andre F.; Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: A retrospective multicenter study. Ann Oncol 2015,26(7),1518

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3